

1F-297-T100

Monoclonal Antibody to CD34 Fluorescein (FITC) conjugated (100 tests)

Clone: 4H11[APG]

Isotype: Mouse IgG1

Specificity: The antibody 4H11[APG] reacts with Class III epitope on CD34 (Mucosialin), a

110-115 kDa monomeric transmembrane phosphoglycoprotein expressed on hematopoietic progenitors cells and on the most pluripotential stem cells; it is gradually lost on progenitor cells. The antibody 4H11[APG] completely blocks binding of Class II antibody QBEnd10 and Class III antibodies BIRMA K3 and

8G12 on KG1a cell line. HLDA VI; WS Code M MA58

Regulatory Status: RUO

Immunogen: Permanent human cell line derived from peripheral leucocytes of a patient suffering

from chronic myeloid leukaemia.

Species Reactivity: Human

Preparation: The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under

optimum conditions. The reagent is free of unconjugated FITC and adjusted for

direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using

20 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension.

The content of a vial (2 ml) is sufficient for 100 tests.

Expiration: See vial label

Lot Number: See vial label

Background: CD34 is a highly glycosylated monomeric 111-115 kDa surface protein, which is

present on many stem cell populations. It is a well established stem cell marker, though its expression on human hematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of hematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro

and in vivo conditions.



PRODUCT DATA SHEET

References:

*Krauter J, Hartl M, Hambach L, Kohlenberg A, Gunsilius E, Ganser A, Heil G: Receptor-mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti-HPCA-1. J Hematother Stem Cell Res. 2001 Dec;10(6):863-71.

*Dao MA, Arevalo J, Nolta JA: Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood. 2003 Jan 1;101(1):112-8.

*Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Gulati S, Luthra PM: Three-dimensional structure prediction of the interaction of CD34 with the SH3 domain of Crk-L. Stem Cells Dev. 2005 Oct:14(5):470-7.

with the SH3 domain of Crk-L. Stem Cells Dev. 2005 Oct;14(5):470-7. *Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Luthra PM: Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem Cells Dev. 2006 Jun;15(3):305-13.

*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997). *Elknerová K, Lacinová Z, Soucek J, Marinov I, Stöckbauer P: Growth inhibitory effect of the antibody to hematopoietic stem cell antigen CD34 in leukemic cell lines. Neoplasma. 2007;54(4):311-20.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.